Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632705 | 0.92 | MAPT (0.50) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL12755264 | 0.84 | MAPT (0.47) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL865299 | 0.83 | L3MBTL1 (0.50) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL10535545 | 0.82 | MAPT (0.49) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL26660809 | 0.79 | RHEB (0.46) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL31501938 | 0.79 | RHEB (0.46) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL1653144 | 0.78 | SRD5A2 (0.64) | MAPTSMN1; SMN2SRD5A2MRGPRX4 | |
| SCHEMBL31501813 | 0.78 | MAPT (0.51) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL26660827 | 0.78 | MAPT (0.51) | MAPTMAPK1TDP1L3MBTL1STAT3 | |
| SCHEMBL4047141 | 0.78 | RAB9A (0.53) | MAPTMAPK1TDP1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-6653304-B2 | Antiarthritic agents; skin disorders; anticarcinogenic agents | BRISTOL-MYERS SQUIBB CO. | 2003-11-25 | — | — | US | disclosed |
| EP-0772592-B1 | 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1254115-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS FOR TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | Bristol-Myers Squibb Company (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-29 | — | — | US | disclosed |
| WO-2001058869-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-0772592-A4 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | LILLY CO ELI (US) | 1998-07-08 | — | — | EP | disclosed |
| US-5641800-A | ALLEVIATE EFFECT OF SEPTIC SHOCK, ADULT RESPIRATORY DISTRESS SYNDROME, PANCREATITIS, TRAUMA, BRONCHIAL ASTHMA, ALLERGIC RHINITIS, AND RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0772592-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003376-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | CNR1, CNR2, GPR18 | MAPT 4708/4885MAPK1 1015/4885TDP1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.